Lv1
50 积分 2021-06-02 加入
免疫抑制剂与结核潜伏感染激活的临床专家共识(2025版)
1个月前
已完结
AJCC cancer staging system - version 9 (2024)
2个月前
已关闭
AJCC Version 9 Cancer Staging System
2个月前
已关闭
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study
3个月前
已完结
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
3个月前
已完结
Lurbinectedin with atezolizumab maintenance therapy in extensive-stage small-cell lung cancer
3个月前
已完结
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study
5个月前
已完结
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
5个月前
已完结
Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer
8个月前
已完结
Mechanism of Action of Antitumor Drug Etoposide: A Review
8个月前
已完结
皖公网安备34019202002308
